11 results
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability and pharmacokinetics of midostaurin in children <18 years of age and >= 3 months who have relapsed or refractory leukemias that may benefit…
Primary: To study the efficacy and tolerability of Midostaurin in patients with indolent or smoldering systemic mastocytosis on mediator symptom reduction.Secondary: 1) To study whether Midostaurin can reduce mast cell infiltration and 2) to assess…
Objective of this study is to determine the efficacy of midostaurin in patients with ASM or MCL with/without an associated hematological clonal non-mast cell lineage disease.
The primary objective of this study is to observe the association between age and mitoPO2 values. The secondary objective is to evaluate whether there is also an association between age and the mitoVO2 values. Further objectives are to investigate…
Primary Objective: the relation between the occurrence of CSA-AKI and the duration of peri-operative low mitoPO2 measurements (<20 mmHg). Secondary Objective:- To study the relationship between the occurrence of postoperative cognitive…
Primary: To determine the MTD and/or RDE of LGH447 with or without midostaurin. Secondary: 1. To characterize the safety and tolerability of LGH447 with or without midostaurin at the MTD and/or RDE.2. To assess any observed antitumor activity of…
Goal: Towards implementation of ART in women with cervical cancer to increase RT precision and reduce the risk of late radiation complications.Study question: What is the effect of bladder filling on the position of the uterus and tumour in women…
Primary objectives: - To test the hypothesis that a relationship between mitochondrial oxygenation and serum lactate existsSecondary objectives:- To provide data for estimating the number of patients needed for a clinical trial to prove the above…
Primary objective:To asses the safety and feasibility of post-transplant panobinostat combined with midostaurin in patients with adverse risk AML/RAEB with FLT3-ITD with high allelic ratio in terms of dose limiting toxicity.Secondary objectives:To…
To compare OS between gilteritinib and midostaurin in combination with induction therapy and consolidation therapy followed by one-year maintenance therapy in patients with newly diagnosed AML with a FLT3 gene mutation eligible for intensive…
Primary objectives:- To assess in a randomized comparison the effect of midostaurin added to 10-day decitabine treatment on the cumulative CR/CRi rate during 3 cycles.Secondary objectives:- To assess the safety and tolerability of midostaurin added…